Can Humanigen’s lenzilumab Prove to be a Gamechanger for the Company?
Humanigen, Inc. (NASDAQ: HGEN) is a clinical-stage biopharmaceutical Company that is focused on creating a portfolio of monoclonal antibodies targeting immunology and immune-oncology disorders. The Company’s lead product candidate is lenzilumab, an anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody, formulated using the Company’s proprietary Humaneered®...
